Comparative Pharmacology
Head-to-head clinical analysis: BUSPAR versus MILTOWN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSPAR versus MILTOWN.
BUSPAR vs MILTOWN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at serotonin 5-HT1A receptors, leading to reduced serotonergic activity; also has antagonist activity at D2 and 5-HT2 receptors.
Miltown (meprobamate) is a carbamate derivative that acts as a central nervous system depressant. Its mechanism of action is not fully understood, but it is believed to exert its effects by modulating GABAergic neurotransmission, possibly by binding to GABA receptors and enhancing inhibitory neurotransmission. It also has sedative, anxiolytic, and muscle relaxant properties.
Initial: 7.5 mg orally twice daily; may increase by 5 mg/day every 2-3 days. Usual: 20-30 mg/day in divided doses; max 60 mg/day.
400 mg orally 3-4 times daily; maximum 2400 mg/day.
None Documented
None Documented
2–3 hours (terminal); clinical context: requires multiple daily dosing; steady-state achieved in ~2 days
10 hours (range 6-17 hours); prolonged in hepatic or renal impairment.
Renal: 29–63% (primarily as metabolites, <1% unchanged); Fecal: 34–38%; Biliary: minimal
Primarily renal, with 10-20% excreted unchanged; remainder as inactive metabolites (e.g., hydroxymeprobamate). Less than 2% fecal.
Category C
Category C
Anxiolytic
Anxiolytic